Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
about
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Cyclosporin A reverses chemoresistance in patients with gynecologic malignanciesPhase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)Molecular pathways: regulation and therapeutic implications of multidrug resistanceRepositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceStrategies for reversing drug resistance.Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know.Clinical relevance of P-glycoprotein in drug therapy.Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposideLimited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestinePharmacokinetics of doxorubicin co-administered with high-dose verapamilCyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancerHigh-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumoursClinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Renal Drug Transporters and Drug Interactions.Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactionsExtraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples.Clinically relevant drug-drug interactions in oncology.CAN a P-gp modulator assist in the control of methotrexate concentrations in the rat brain? -inhibitory effects of rhodamine 123, a specific substrate for P-gp, on methotrexate excretion from the rat brain and its optimal route of administration.P glycoprotein (P-gp) and drug resistance--time for reappraisal?Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.Obstacles to Brain Tumor Therapy: Key ABC Transporters.Approaches to multidrug resistance reversal.Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.G2677T and C3435T Genotype and Haplotype Are Associated With HepaticABCB1(MDR1) Expression
P2860
Q30234940-EAC7B4B2-584C-4A32-9E6C-13BEC822E97BQ30444746-144F28A9-1360-4634-AFA3-F354A3DC22D8Q33333473-F18A00AC-2E3D-462D-9B49-85BBF285FFD3Q33729158-3A59147F-73BF-4A8C-8839-B5088613BD9EQ33758413-94B7E5EC-9C65-42AA-B1BE-B0B7A08E7776Q34255292-9B3ABB41-BE5E-4D5C-A0F7-3BE58045B91BQ34774854-3648CE2C-835A-414A-A52B-984CB2DC404AQ35567287-350CB3D1-B77C-4598-B0CA-2C9BADF08165Q35608207-9837A9F8-F4D0-4734-ACEC-D7372B76B83CQ35620664-86CD0861-5A88-4972-932B-4B9F8F603865Q35983126-EF6918CC-F6DF-4F87-8997-4B605BB01E05Q36031211-82EEFEA5-728B-4B2F-8997-9D9B3DFCC859Q36079867-51FFE8AD-AD6E-4B06-AE97-7D1F5EAC77ABQ36116213-66DF5348-E71B-4843-8A29-1DE2201059BCQ36135012-321F4DBE-A8D3-4F89-B5F3-D43929A80F41Q36292342-1469879D-3313-4036-A77A-021DC3127F38Q36292923-05CD9FCB-EB97-4CC7-9565-2A87BA0A710DQ37334707-3FD49D89-1FFA-4921-8B7C-76A5BA684D6FQ37355856-E9BFD948-6BD8-4625-94D4-B4A2479CD313Q38099040-2125355D-3003-4215-8A0D-6526BE3FDE29Q39140289-11FFBA08-62CE-4DCC-A22E-304863046E30Q40978951-C1125FFD-94AD-4DCC-B82A-E440F214E2B5Q41030442-050EC590-18CA-4E80-9302-E094C51D726EQ41937519-35E351CF-2DFB-4261-8C58-7B4E17F47083Q42284655-AB6D3C7B-411B-4DAD-ADEE-2A2E0E27A408Q42319809-FF431B24-7C6B-4068-933E-81225531D84AQ42390230-A34CC301-E3F0-4DE4-A103-AE612C2C79DEQ42930123-CA509952-0BA5-4E57-9A1A-7732CAA5E8AEQ44797030-FA76E1C9-704F-4128-A1F3-1FEACAF9DA00Q45869623-1F51B162-BB5E-4EB4-A09B-BD34C44B1B94Q47944360-479DA34A-DEC7-440A-A348-D41595246A00Q53852784-53775173-3004-4916-8D00-975C1EFD8C70Q54185360-AA358F82-1A61-4A87-B739-5AD75F419DD6Q58869653-83733CF5-6B82-4919-BE9C-E64D7620686D
P2860
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Alteration of etoposide pharma ...... modulate multidrug resistance.
@ast
Alteration of etoposide pharma ...... modulate multidrug resistance.
@en
Alteration of etoposide pharma ...... modulate multidrug resistance.
@nl
type
label
Alteration of etoposide pharma ...... modulate multidrug resistance.
@ast
Alteration of etoposide pharma ...... modulate multidrug resistance.
@en
Alteration of etoposide pharma ...... modulate multidrug resistance.
@nl
prefLabel
Alteration of etoposide pharma ...... modulate multidrug resistance.
@ast
Alteration of etoposide pharma ...... modulate multidrug resistance.
@en
Alteration of etoposide pharma ...... modulate multidrug resistance.
@nl
P2093
P1476
Alteration of etoposide pharma ...... modulate multidrug resistance.
@en
P2093
A M Yahanda
M P Gosland
N A Brophy
S Kaubisch
P304
P356
10.1200/JCO.1992.10.10.1635
P407
P577
1992-10-01T00:00:00Z